SMMT - NASDAQ
Summit Therapeutics Inc.
$15.07
+1.4%Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotSummit Therapeutics Inc. Management Team
Mr. Bhaskar Anand
Chief Accounting Officer
Dr. Fong Clow
Chief Biometrics Officer
Mr. Dave Gancarz
Chief Business & Strategy Officer
Ms. Shelley D. Spray
Chief Education & Brand Officer
Dr. Allen S. Yang M.D., Ph.D.
Chief Medical Officer
Mr. Manmeet Singh Soni CPA
Chief Operating Officer, Chief Financial Officer & Director
Compensation
$1,261,021
Dr. Urte Gayko Ph.D.
Chief Regulatory, Quality & Pharmacovigilance Officer
Mr. Robert W. Duggan
Co-Chief Executive Officer & Executive Chairman
Compensation
$158,613
Dr. Mahkam Zanganeh D.D.S., M.B.A.
Co-Chief Executive Officer, President & Director
Compensation
$1,161,021
Prof. Dame Kay Davies DBE, FRS CBE
Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Dr. Allen S. Yang M.D., Ph.D.
Head of R&D Strategy
Mr. Nathan LiaBraaten
Senior Director of Investor Relations
Summit Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $22.97M worth of SMMT shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
1.3M
22.97M
0
0.00
+23.0M
+$22.97M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Xia Yu
Director
$10.00M
Duggan Robert W
Director, 10 Percent Owner, Officer: Co-Chief Executive Officer
$6.48M
Zanganeh Mahkam
Director, 10 Percent Owner, Officer: Co-Chief Executive Officer
$6.48M
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $22.97M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
SMMT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | April 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 14, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 19, 2023 | October 12, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | May 23, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | December 13, 2022 | January 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | July 06, 2022 | July 06, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 16, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.